سعر فيروجيكت 12.5مجم/مل امبول 2022

Parenteral iron preparation, 12.5 mg/ml iron, ampoule for intravenous infusion or slow intravenous injection (ADWIA).

• Intravenous iron products are contraindicated in hypersensitivity to the active substance or excipients, and in serious hypersensitivity to other parenteral iron products.General active-ingredient information · European Medicines Agency (EMA)

• All intravenous iron preparations can cause serious hypersensitivity reactions, which can be fatal; caution is needed with every dose, even if previous doses were tolerated, and a test dose is no longer recommended.General active-ingredient information · European Medicines Agency (EMA)
• Give intravenous iron only where staff trained to manage anaphylactic reactions and resuscitation facilities are immediately available; stop the infusion immediately if hypersensitivity occurs.General active-ingredient information · European Medicines Agency (EMA)
• The risk of hypersensitivity is higher in patients with known allergies, immune or inflammatory conditions (e.g. rheumatoid arthritis) or a history of severe asthma, eczema or other atopic allergy.General active-ingredient information · European Medicines Agency (EMA)

• Intravenous iron should not be used during pregnancy unless clearly necessary; treatment should be confined to the second or third trimester when benefits clearly outweigh risks such as fetal anoxia and distress from maternal hypersensitivity.General active-ingredient information · European Medicines Agency (EMA)

• Observe patients closely for signs and symptoms of hypersensitivity during and for at least 30 minutes after each intravenous iron injection.General active-ingredient information · European Medicines Agency (EMA)

English text not available for this section.